Literature DB >> 28966213

Elevated Serum Anti-GM-CSF Antibodies before the Onset of Autoimmune Pulmonary Alveolar Proteinosis in a Patient with Sarcoidosis and Systemic Sclerosis.

Mari Yamasue1, Shin-Ichi Nureki1, Yuko Usagawa1, Tomoko Ono1, Hiroyuki Matsumoto1, Takamasa Kan1, Jun-Ichi Kadota1.   

Abstract

Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of periodic acid-schiff stain-positive lipoproteinaceous materials in the alveolar space due to impaired surfactant clearance by alveolar macrophage. Autoimmune PAP is the most common form of PAP, but rarely accompanies collagen disease or sarcoidosis. We report here a rare case of autoimmune PAP preceded by systemic sclerosis and sarcoidosis. A 64-year-old woman was admitted to our hospital for blurred vision, muscle weakness of extremities, Raynaud's phenomenon, and exertional dyspnea. We diagnosed her as having systemic sclerosis complicated with sarcoidosis. Chest computed tomography (CT) and transbronchial lung biopsy showed the findings of pulmonary fibrosis without PAP. We treated her with corticosteroid and intravenous cyclophosphamide therapy, followed by tacrolimus therapy. Thereafter, her symptoms improved except for exertional dyspnea, and she began to complain of productive cough thirteen months after corticosteroid and immunosuppressant therapy. On the second admission, a chest CT scan detected the emergence of crazy-paving pattern in bilateral upper lobes. Bronchoalveolar lavage (BAL) fluid with milky appearance and a lung biopsy specimen revealed acellular periodic acid-schiff stain-positive bodies. The serum titer of anti-granulocyte macrophage colony stimulating factor (GM-CSF) antibodies was elevated on first admission and remained high on second admission. We thus diagnosed her as having autoimmune PAP. Reducing the dose of immunosuppressive agents and repeating the segmental BAL resulted in the improvement of her symptoms and radiological findings. Immunosuppressant therapy may trigger the onset of autoimmune PAP in a subset of patients with systemic sclerosis and/or sarcoidosis.

Entities:  

Keywords:  anti-granulocyte macrophage colony stimulating factor antibodies; autoimmune pulmonary alveolar proteinosis; immunosuppressant therapy; sarcoidosis; systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28966213     DOI: 10.1620/tjem.243.77

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

Review 1.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

2.  Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report.

Authors:  S Sato; K Akasaka; H Ohta; Y Tsukahara; G Kida; E Tsumiyama; K Kusano; T Oba; T Nishizawa; R Kawabe; H Yamakawa; M Amano; H Matsushima; T Takada
Journal:  BMC Pulm Med       Date:  2020-04-06       Impact factor: 3.317

3.  Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody.

Authors:  Toru Arai; Takahiko Kasai; Kazunori Shimizu; Kunimitsu Kawahara; Kanako Katayama; Chikatoshi Sugimoto; Masaki Hirose; Hiroyuki Okamoto; Kazunobu Tachibana; Masanori Akira; Yoshikazu Inoue
Journal:  Intern Med       Date:  2020-06-30       Impact factor: 1.271

4.  Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis.

Authors:  Kanako Katayama; Masaki Hirose; Toru Arai; Kazuyoshi Hatsuda; Kazunobu Tachibana; Reiko Sugawara; Chikatoshi Sugimoto; Takahiko Kasai; Masanori Akira; Yoshikazu Inoue
Journal:  Orphanet J Rare Dis       Date:  2020-09-29       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.